Palisade Bio, Inc. (PALI) stock
PALINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.01−0.02 (-1.94%)
Close on Nov 17, 2026Market cap $176.01MP/E –Yield –
Earnings
Palisade Bio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.07
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Palisade Bio's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 10, 2026after the close | – | – | -$0.07 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 10, 2026after the close | $500.00K | – | -$0.05 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 12, 2026after the close | – | – | -$0.05 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 27, 2024after the close | – | – | – | Release |
| Q4 FY2020ended Dec 31, 2020 | Mar 23, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 16, 2020after the close | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 14, 2020during market hours | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 15, 2020during market hours | – | – | – | Filing |
| Q3 FY2019ended Sep 30, 2019 | Nov 15, 2019during market hours | – | – | – | Filing |
| Q2 FY2019ended Jun 30, 2019 | Aug 14, 2019during market hours | – | – | – | Filing |
| Q1 FY2019ended Mar 31, 2019 | May 14, 2019after the close | – | – | – | Filing |
| Q4 FY2018ended Dec 31, 2018 | Mar 22, 2019after the close | – | – | – | Filing |
| Q3 FY2018ended Sep 30, 2018 | Nov 16, 2018before the open | – | – | – | Filing |
| Q2 FY2018ended Jun 30, 2018 | Aug 15, 2018after the close | – | – | – | Filing |
| Q1 FY2018ended Mar 31, 2018 | May 15, 2018before the open | – | – | – | Filing |
| Q3 FY2017ended Sep 30, 2017 | Nov 15, 2017after the close | – | – | – | Filing |
| Q2 FY2017ended Jun 30, 2017 | Aug 8, 2017before the open | – | – | – | Filing |
| Q1 FY2017ended Mar 31, 2017 | May 12, 2017after the close | – | – | – | Filing |
| Q4 FY2016ended Dec 31, 2016 | Mar 23, 2017during market hours | – | – | – | Filing |
| Q3 FY2016ended Sep 30, 2016 | Nov 8, 2016after the close | – | – | – | Filing |
| Q2 FY2016ended Jun 30, 2016 | Aug 11, 2016after the close | – | – | – | Filing |
| Q1 FY2016ended Mar 31, 2016 | May 12, 2016after the close | – | – | – | Filing |
| Q4 FY2015ended Dec 31, 2015 | Mar 14, 2016after the close | – | – | – | Filing |
| Q3 FY2015ended Sep 30, 2015 | Nov 10, 2015after the close | – | – | – | Filing |
| Q2 FY2015ended Jun 30, 2015 | Aug 10, 2015after the close | – | – | – | Filing |
| Q1 FY2015ended Mar 31, 2015 | May 8, 2015after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Palisade Bio has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Palisade Bio puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Palisade Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- News
- News
- News
- News
- News
- News
- News
- News
- News
- Results
- News
See a number that looks wrong?